CLYM (Climb Bio) Other Income (Expense) : $4.42 Mil (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Climb Bio Other Income (Expense)?

Climb Bio's other income expense for the Climb Bio's pretax income for the three months ended in Sep. 2024 was $2.84 Mil. Its other income expense for the trailing twelve months (TTM) ended in Sep. 2024 was $4.42 Mil.

Climb Bio Other Income (Expense) Historical Data

The historical data trend for Climb Bio's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Climb Bio Other Income (Expense) Chart

Climb Bio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Other Income (Expense)

-1.85

-8.90

-11.81

-1.48

0.54

Climb Bio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Income (Expense)	Get a 7-Day Free Trial															-0.23	0.13	-0.03	1.48	2.84

Climb Bio Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.42 Mil.

Climb Bio (NAS:CLYM) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Climb Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Climb Bio Inc (NAS:CLYM) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

N/A

Address

2801 Centerville Road, 1st Floor, PMB No.117, Wilmington, DE, USA, 19808-1609

Website

https://www.climbbio.com

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.

Executives

Emily Pimblett	officer: Chief Accounting Officer	C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Valerie Morisset	officer: Chief Scientific Officer	C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ai Eti Llc	10 percent owner	C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Judith Dunn	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Andrew David Levin	director	C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Simon Tate	director	C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Adam Joseph Rosenberg	director	C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
James B Bucher	officer: EVP and General Counsel	11804 NORTH CREEK PARKWAY S, BOTHELL WA 98011
Ra Capital Nexus Fund Ii, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Erin Lavelle	officer: COO & CFO	C/O ALDER BIOPHARMACEUTICALS, INC., 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Ra Capital Nexus Fund, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Len Blavatnik	other: Affiliate of 10% Owner	C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019
Liam Ratcliffe	director	C/O ACCESS INDUSTRIES, INC, 40 WEST 57TH ST, 28TH FLOOR, NEW YORK NY 10019
Robert Azelby	director, officer: Chief Executive Officer	307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109